The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform
Jia Wei Zheng - One of the best experts on this subject based on the ideXlab platform.
-
treatment of kaposiform hemangioendothelioma and Tufted Angioma
International Journal of Cancer, 2016Co-Authors: Xiaohan Liu, Wei Li Yan, Ling Zhang, Chi Yang, Jia Wei ZhengAbstract:This meta-analysis was to evaluate the efficacy of current treatment modalities for kaposiform hemangioendothelioma and Tufted Angioma. A systematic review was performed using PubMed (Medline), Web of Science and Embase for clinical studies. The outcome was measured by pooled response rate with 95% confidence intervals (CIs), together with heterogeneity, subgroup analysis, sensitivity analysis and publication bias. Fifteen studies with 244 participants were included in this analysis. Vincristine therapy exhibited a relatively higher response rate (0.72; 95%CI, 0.64-0.79) compared with other therapies including systemic corticosteroid (0.27; 95%CI, 0.17-0.36), interferon (0.36; 95%CI, 0.24-0.48), radiotherapy (0.49; 95%CI, 0.26-0.73), embolization (0.66; 95%CI, 0.48-0.83), aspirin/ticlopidine (0.42; 95%CI, 0.06-0.78) and sirolimus (0.57; 95%CI, 0.00-0.10), in treating KHE/TA. Subgroup analysis indicated that the efficacy of systemic corticosteroids therapy was age-related. The pooled response rate was 0.15 (95%CI, 0.08-0.23) for participants 3.5 months of age and older compared with 0.35 (95% CI, 0.26-0.44) for participants less than 3.5 months. Regarding side effects, systemic corticosteroids treatment was 0.32 (95%CI, 0.15-0.50), vincristine modality was 0.16 (95%CI, 0.08-0.24) and interferon therapy was 0.28 (95%CI, 0.13-0.43). In conclusion, as one of the first reviews evaluating the effect of common therapies in the treatment of KHE/TA, our meta-analysis displayed that vincristine was more effective. Thus, vincristine was the most effective, providing evidence supporting the use of vincristine as a first-line therapy for KHE/TA.
-
clinical outcomes for systemic corticosteroids versus vincristine in treating kaposiform hemangioendothelioma and Tufted Angioma
Medicine, 2016Co-Authors: Xiaohan Liu, Wei Li Yan, Ling Zhang, Chi Yang, Shanyong Zhang, Jia Wei ZhengAbstract:A meta-analysis was performed to evaluate the efficacy and safety of systemic corticosteroids versus those of vincristine in the treatment of kaposiform hemangioendothelioma (KHE) and Tufted Angioma (TA). A literature search of PubMed, Embase, and Web of Science was performed for clinical studies on systemic corticosteroid versus vincristine therapies in treating KHE/TA. Pooled relative risks (RRs) and response rate with 95% confidence intervals (CIs) were used to measure outcomes. Heterogeneity, subgroup analysis, sensitivity analysis, and publication bias analysis were performed for result evaluation. Thirteen studies, comprising 344 participants, were used in the analysis. Vincristine therapy was found to be relatively more effective than systemic corticosteroids (RRs = 0.45, 95%CI: 0.35–0.58). The result of pooled adverse reactions response rate for systemic corticosteroids was 0.31 (95%CI, 0.18–0.43), significantly higher than that for vincristine, which was 0.12 (95%CI, 0.06–0.19). In subgroup analyses, factors including mean age and race of patients, and period of follow-up were examined as possible sources of heterogeneity. This is the first meta-analysis estimating the clinical outcomes of systemic corticosteroids in comparison with those of vincristine in the treatment of KHE/TA. The results showed that vincristine was considerably more effective with lower complication rates than systemic corticosteroids; thus, vincristine could be suggested as the first-line therapy for KHE/TA.
Wenying Chen - One of the best experts on this subject based on the ideXlab platform.
-
imiquimod 5 cream for an annular plaque with progressive pain on the right distal arm in the cubital fossa acquired Tufted Angioma
Clinical Cosmetic and Investigational Dermatology, 2021Co-Authors: Jia Wang, Wenying ChenAbstract:Tufted Angioma, also known as angioblastoma, is a rare benign vascular neoplasm of the skin and subcutaneous tissue. The natural history of Tufted Angioma is slow, progressive growth for several years, and tends to remain stable thereafter, resulting in disfiguring appearance. The main choice of treatment for Tufted Angioma is complete surgical excision, but local recurrence is frequent. Here, we report a 33-year-old woman with a four-year history of a steadily increasing pink to violaceous plaque on her right arm accompanied by spontaneous, progressive pain over the last seven months. Histology revealed multiple separated lobules of spindle cells throughout the dermis and subcutaneous tissue to the deep margin, with numerous mitoses but no cellular atypia, the small capillary-sized vessels scattered within the lobules, which were consistent with Tufted Angioma. To our satisfaction, her pain disappeared and the whole plaque was significantly improved after a four-month course of external application with imiquimod 5% cream.
Ilona J Frieden - One of the best experts on this subject based on the ideXlab platform.
-
congenital self regressing Tufted Angioma
Archives of Dermatology, 2006Co-Authors: John Browning, Ilona J Frieden, Eulalia Baselga, Annette Wagner, Denise W MetryAbstract:Background Tufted Angioma (known in Japanese literature as angioblastoma of Nakagawa) is an uncommon, histologically benign, vascular tumor. Lesions typically present during infancy or early childhood and are most commonly reported to persist and/or expand over time. Congenital presentations are rare, as are reports of spontaneous regression. Observations We present a series of 5 histopathologically confirmed cases of congenital Tufted Angioma that spontaneously regressed during infancy or early childhood. We also review the literature, focusing on both congenital and early-onset cases in infants. Conclusion We recommend that observation for potential regression be considered for otherwise uncomplicated congenital or early infantile cases of Tufted Angioma.
-
kaposiform hemangioendothelioma without kasabach merritt phenomenon
Journal of The American Academy of Dermatology, 2005Co-Authors: Alla Gruman, Francine Blei, Marilyn G Liang, John B Mulliken, Steven J Fishman, Patricia E Burrows, Harry P W Kozakewich, Ilona J FriedenAbstract:Kasabach-Merritt phenomenon is a serious coagulopathy associated with kaposiform hemangioendothelioma (KHE), Tufted Angioma, and possibly other vascular neoplasms. KHE presenting in the absence of Kasabach-Merritt phenomenon is rare, although Tufted Angioma frequently occurs without thrombocytopenia. We retrospectively reviewed 10 cases of KHE without Kasabach-Merritt phenomenon. The tumors appeared as soft tissue masses with the overlying skin being either normal, erythematous, or violaceous. There were no radiologic or microscopic differences in noncoagulopathic KHE as compared with coagulopathic KHE. Evidence of platelet trapping and hemosiderin deposition was seen histologically, despite normal serum platelet levels. All KHE were less than 8 cm in diameter, suggesting that tumors that grow no larger than this size are less likely to trap platelets in sufficient quantity to cause thrombocytopenia. Our series confirms that KHE appears with a wide spectrum of behavior and response to treatment. The decision as to whether or not to treat a noncoagulopathic KHE should be based on the size and location of the tumor and the possible side effects of therapy.
Denise W Metry - One of the best experts on this subject based on the ideXlab platform.
-
variable response to propranolol treatment of kaposiform hemangioendothelioma Tufted Angioma and kasabach merritt phenomenon
Pediatric Blood & Cancer, 2012Co-Authors: Yvonne E Chiu, Beth A Drolet, Francine Blei, Manuel Carcao, Jason Fangusaro, Michael E Kelly, Alfons Krol, Sabra Lofgren, Anthony J Mancini, Denise W MetryAbstract:Propranolol is a non-selective beta-adrenergic antagonist successfully used in a case of kaposiform hemangioendothelioma (KHE) associated with Kasabach-Merritt phenomenon (KMP). We report 11 patients treated with propranolol for KHE and the related variant Tufted Angioma (TA), six of whom also had KMP. The varied responses to treatment, with only 36% responding in our series, demonstrate the need for further study of this medication before routine use for these indications.
-
variable response to propranolol treatment of kaposiform hemangioendothelioma Tufted Angioma and kasabach merritt phenomenon
Pediatric Blood & Cancer, 2012Co-Authors: Yvonne E Chiu, Beth A Drolet, Francine Blei, Manuel Carcao, Jason Fangusaro, Michael E Kelly, Alfons Krol, Sabra Lofgren, Anthony J Mancini, Denise W MetryAbstract:Propranolol is a non-selective beta-adrenergic antagonist successfully used in a case of kaposiform hemangioendothelioma associated with Kasabach-Merritt phenomenon. We report eleven patients treated with propranolol for kaposiform hemangioendothelioma and the related variant Tufted Angioma, six of whom also had Kasabach-Merritt phenomenon. The varied responses to treatment, with only 36% responding in our series, demonstrate the need for further study of this medication before routine use for these indications.
-
congenital self regressing Tufted Angioma
Archives of Dermatology, 2006Co-Authors: John Browning, Ilona J Frieden, Eulalia Baselga, Annette Wagner, Denise W MetryAbstract:Background Tufted Angioma (known in Japanese literature as angioblastoma of Nakagawa) is an uncommon, histologically benign, vascular tumor. Lesions typically present during infancy or early childhood and are most commonly reported to persist and/or expand over time. Congenital presentations are rare, as are reports of spontaneous regression. Observations We present a series of 5 histopathologically confirmed cases of congenital Tufted Angioma that spontaneously regressed during infancy or early childhood. We also review the literature, focusing on both congenital and early-onset cases in infants. Conclusion We recommend that observation for potential regression be considered for otherwise uncomplicated congenital or early infantile cases of Tufted Angioma.
Xiaohan Liu - One of the best experts on this subject based on the ideXlab platform.
-
treatment of kaposiform hemangioendothelioma and Tufted Angioma
International Journal of Cancer, 2016Co-Authors: Xiaohan Liu, Wei Li Yan, Ling Zhang, Chi Yang, Jia Wei ZhengAbstract:This meta-analysis was to evaluate the efficacy of current treatment modalities for kaposiform hemangioendothelioma and Tufted Angioma. A systematic review was performed using PubMed (Medline), Web of Science and Embase for clinical studies. The outcome was measured by pooled response rate with 95% confidence intervals (CIs), together with heterogeneity, subgroup analysis, sensitivity analysis and publication bias. Fifteen studies with 244 participants were included in this analysis. Vincristine therapy exhibited a relatively higher response rate (0.72; 95%CI, 0.64-0.79) compared with other therapies including systemic corticosteroid (0.27; 95%CI, 0.17-0.36), interferon (0.36; 95%CI, 0.24-0.48), radiotherapy (0.49; 95%CI, 0.26-0.73), embolization (0.66; 95%CI, 0.48-0.83), aspirin/ticlopidine (0.42; 95%CI, 0.06-0.78) and sirolimus (0.57; 95%CI, 0.00-0.10), in treating KHE/TA. Subgroup analysis indicated that the efficacy of systemic corticosteroids therapy was age-related. The pooled response rate was 0.15 (95%CI, 0.08-0.23) for participants 3.5 months of age and older compared with 0.35 (95% CI, 0.26-0.44) for participants less than 3.5 months. Regarding side effects, systemic corticosteroids treatment was 0.32 (95%CI, 0.15-0.50), vincristine modality was 0.16 (95%CI, 0.08-0.24) and interferon therapy was 0.28 (95%CI, 0.13-0.43). In conclusion, as one of the first reviews evaluating the effect of common therapies in the treatment of KHE/TA, our meta-analysis displayed that vincristine was more effective. Thus, vincristine was the most effective, providing evidence supporting the use of vincristine as a first-line therapy for KHE/TA.
-
clinical outcomes for systemic corticosteroids versus vincristine in treating kaposiform hemangioendothelioma and Tufted Angioma
Medicine, 2016Co-Authors: Xiaohan Liu, Wei Li Yan, Ling Zhang, Chi Yang, Shanyong Zhang, Jia Wei ZhengAbstract:A meta-analysis was performed to evaluate the efficacy and safety of systemic corticosteroids versus those of vincristine in the treatment of kaposiform hemangioendothelioma (KHE) and Tufted Angioma (TA). A literature search of PubMed, Embase, and Web of Science was performed for clinical studies on systemic corticosteroid versus vincristine therapies in treating KHE/TA. Pooled relative risks (RRs) and response rate with 95% confidence intervals (CIs) were used to measure outcomes. Heterogeneity, subgroup analysis, sensitivity analysis, and publication bias analysis were performed for result evaluation. Thirteen studies, comprising 344 participants, were used in the analysis. Vincristine therapy was found to be relatively more effective than systemic corticosteroids (RRs = 0.45, 95%CI: 0.35–0.58). The result of pooled adverse reactions response rate for systemic corticosteroids was 0.31 (95%CI, 0.18–0.43), significantly higher than that for vincristine, which was 0.12 (95%CI, 0.06–0.19). In subgroup analyses, factors including mean age and race of patients, and period of follow-up were examined as possible sources of heterogeneity. This is the first meta-analysis estimating the clinical outcomes of systemic corticosteroids in comparison with those of vincristine in the treatment of KHE/TA. The results showed that vincristine was considerably more effective with lower complication rates than systemic corticosteroids; thus, vincristine could be suggested as the first-line therapy for KHE/TA.
